By Marie Rosenthal
The FDA recently approved darunavir, cobicistat, emtricitabine, tenofovir alafenamide (D/C/F/TAF; Symtuza, Janssen), the first complete darunavir (DRV)-based, single-tablet regimen (STR) for the treatment of HIV-1.
DRV is a protease inhibitor (PI); cobicistat (COBI; Gilead), a cytochrome P450 3A inhibitor; and emtricitabine (FTC; Gilead) and tenofovir alafenamide (TAF; Gilead) are both nucleoside analog reverse transcriptase inhibitors.